English

Natural Defects Positive Control

Natural Defect Positive Controls are purpose-built samples containing engineered flaws that replicate typical defects occurring during manufacturing, or transit—such as glass micro-cracks, stopper scratches, incomplete crimps, or syringe component gaps. They bridge the gap between controlled laboratory testing and real-world package failure risks.

Inquire Now

Fill in the information

verify

Typical Applications

More Solutions

Core Value

Since real leaks are seldom perfect holes, regulators emphasize detecting "probable defects." Our positive controls address this need directly.

 

○ Real-World Relevance: Confirms your CCIT method can detect challenging, non-ideal defect types that pose actual risks, strengthening your validation package.

 

○ Process Risk Insight: Helps identify vulnerabilities in your packaging process. For example, simulators modeling "over-compressed stoppers" can verify the safety of capper settings.

 

○ Faster Root-Cause Analysis: Provides a comparative testing for investigating production leaks, accelerating troubleshooting and corrective actions.

 

Complete Solution


We support the custom development of defect simulators based on your specific failure history or concerns, helping you close the loop between testing data and production quality improvements.

More Information

  • Related articles
  • Frequently Asked Questions
  • Q:

    What is the difference between probabilistic and deterministic test methods?

    A:

    Probabilistic and deterministic methods differ fundamentally in principle, output, and reliability.

    - Probabilistic methods (e.g., microbial ingress, dye ingress) – Results are influenced by variable factors. Output is typically qualitative or semi‑quantitative, and cannot precisely locate or size leaks. They provide probability‑based, indirect evidence of integrity.


    - Deterministic methods (e.g., vacuum decay, laser-based headspace analysis) – Based on physical principles, measuring quantifiable parameters to directly detect leaks. Results are objective, quantitative, and highly repeatable, enabling calibration, trend analysis, and statistical process control. They provide a higher level of assurance and reliability.

  • Q:

    What is Container Closure Integrity (CCI)?

    A:

    Container Closure Integrity (CCI) refers to the ability of a packaging system to prevent product loss, microbial ingress, and entry of gases (oxygen, air, water vapor, etc.) or other substances, thereby ensuring that the drug product remains safe and meets quality standards throughout its shelf life.

     

    For injectable packaging systems, CCI requirements fall into three categories:

    1. maintain sterility and product composition without the need to preserve headspace gas;

    2. maintain sterility, product composition, and headspace gas;

    3. for multi-dose containers that must maintain sterility after opening – prevent microbial ingress and product leakage during use. CCI studies for injectable products should be tailored to product characteristics.

     

    A packaging system is generally considered to have acceptable CCI when it has passed or is capable of passing a microbial challenge test. In a broader sense, CCI means the absence of any leakage that could compromise drug quality. Based on scientific research and risk assessment, the Maximum Allowable Leakage Limit (MALL) should be determined considering packaging composition and assembly, product contents, and the environment to which the product may be exposed over its lifecycle. If a package’s leakage does not exceed its MALL, the closure system is considered integral.

  • Q:

    Which regulations and guidelines address Container Closure Integrity?

    A:

    Key regulatory and technical guidance documents for CCI include:

     

    - EU GMP Annex 1 – Mandates container closure integrity verification and testing for terminally sterilized products, with differentiated requirements based on container type.

    - USP <1207> – A comprehensive technical guide widely accepted as the industry standard, systematically describing test method categories, selection, validation, and lifecycle application. FDA guidance also permits physical CCI testing as an alternative to some sterility tests in stability studies.

    - China NMPA – "Technical Guideline for Packaging System Integrity Study of Chemical Injectables (Trial)" – Signals increasing regulatory attention and alignment with international standards.

Why Choose Zholion?

Contact Us Now